Published in PLoS One on June 17, 2011
Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One (2012) 1.04
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. PLoS One (2015) 0.83
Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells. Immunol Cell Biol (2016) 0.80
HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med (2014) 0.77
Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget (2015) 0.76
Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. Oncoimmunology (2016) 0.75
Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. Mol Ther (2017) 0.75
Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget (2017) 0.75
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 5.32
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92
Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med (2002) 4.67
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 4.17
Danger signals: SOS to the immune system. Curr Opin Immunol (2001) 3.91
Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med (2002) 3.35
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
TLR3 can directly trigger apoptosis in human cancer cells. J Immunol (2006) 2.79
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev (2008) 2.72
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol (2004) 2.65
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood (2003) 2.50
The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol (2005) 2.43
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol (2003) 2.34
Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol (1998) 2.27
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 2.17
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta (2009) 2.07
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol (2003) 2.04
NK cells at the interface between innate and adaptive immunity. Cell Death Differ (2007) 1.83
Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol (1999) 1.82
NK cell receptors and their ligands in leukemia. Leukemia (2007) 1.78
The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol (2008) 1.69
Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol (1999) 1.68
Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med (2009) 1.67
Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res (2007) 1.67
Recognition of autologous dendritic cells by human NK cells. Eur J Immunol (1999) 1.63
Targeting of human dendritic cells by autologous NK cells. J Immunol (1999) 1.62
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res (2006) 1.61
The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol (2003) 1.60
Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma. PLoS Pathog (2008) 1.60
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol (2008) 1.57
Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med (2009) 1.51
Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev (2008) 1.48
Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A (2006) 1.42
Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol (2005) 1.42
Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol (2008) 1.42
Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol (2001) 1.41
Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood (2002) 1.34
Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol (2005) 1.33
Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood (2001) 1.33
Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res (2000) 1.30
The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol (2006) 1.30
Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood (2004) 1.29
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol (2004) 1.21
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother (2008) 1.15
Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther (2005) 1.15
Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol (2007) 1.14
p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood (2004) 1.14
TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol (2010) 1.13
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother (2010) 1.13
Dendritic cell interactions with NK cells from different tissues. J Clin Immunol (2009) 1.12
IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol (2005) 1.11
Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res (2002) 1.09
Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res (2002) 1.08
Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother (2005) 1.08
Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol (2004) 1.07
Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol (2008) 1.07
Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood (2010) 1.05
NK cells: innate immunity against hematological malignancies? Trends Immunol (2004) 1.03
Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol (2010) 1.02
TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells. J Immunol (2005) 1.02
Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. Cancer Immunol Immunother (2009) 0.99
Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw (2002) 0.99
Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res (1999) 0.98
The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother (2009) 0.97
Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother (2009) 0.95
Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol (2006) 0.95
Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med (2007) 0.93
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother (2008) 0.92
Missing self, NK cells, and The White Album. J Immunol (2005) 0.92
Immunotherapy of acute myeloid leukemia: current approaches. Oncologist (2009) 0.92
Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. Biochem Pharmacol (2009) 0.91
Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells. Int J Cancer (2009) 0.90
Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res (2002) 0.89
Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. Blood (2005) 0.89
Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res (2010) 0.85
Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells. J Immunol (2009) 0.84
Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol (2008) 0.84
Viral immunity: cross-priming with the help of TLR3. Curr Biol (2005) 0.83
Double stranded RNA- relative to other TLR ligand-activated dendritic cells induce extremely polarized human Th1 responses. Cell Immunol (2010) 0.82
Learning from viruses: the necrotic bodies of tumor cells with intracellular synthetic dsRNA induced strong anti-tumor immune responses. Pharm Res (2007) 0.81
Self-tolerance, dendritic cell (DC)-mediated activation and tissue distribution of natural killer (NK) cells. Immunol Lett (2007) 0.80
Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells. Leukemia (2007) 0.80
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 4.68
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Cell cycle and apoptosis. Cell Prolif (2003) 1.59
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 1.47
Apoptosis: mechanisms and relevance in cancer. Ann Hematol (2005) 1.44
Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol (2007) 1.44
mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther (2007) 1.40
Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood (2012) 1.23
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy (2009) 1.09
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist (2012) 1.07
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med (2009) 1.05
Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One (2012) 1.04
The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein. Eur J Hum Genet (2011) 1.03
Dendritic cell-based cancer gene therapy. Hum Gene Ther (2009) 1.02
Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets (2004) 1.01
Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells. J Immunother (2006) 0.99
Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. BMC Biotechnol (2009) 0.98
Clinical potential of intravenous neural stem cell delivery for treatment of neuroinflammatory disease in mice? Cell Transplant (2010) 0.98
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood (2005) 0.98
A maximal exercise bout increases the number of circulating CD34+/KDR+ endothelial progenitor cells in healthy subjects. Relation with lipid profile. J Appl Physiol (1985) (2008) 0.97
The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother (2009) 0.97
Current challenges for the advancement of neural stem cell biology and transplantation research. Stem Cell Rev (2012) 0.96
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res (2013) 0.96
Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res (2010) 0.95
Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy. Brain (2009) 0.94
Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin (2011) 0.93
Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol (2002) 0.93
CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology (2013) 0.93
Immunotherapy of acute myeloid leukemia: current approaches. Oncologist (2009) 0.92
Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy (2012) 0.91
Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord. BMC Biotechnol (2007) 0.90
Dysphagia lusoria. CMAJ (2009) 0.88
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS (2012) 0.88
Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation. Immunol Cell Biol (2009) 0.87
Human C-reactive protein activates monocyte-derived dendritic cells and induces dendritic cell-mediated T-cell activation. Arterioscler Thromb Vasc Biol (2008) 0.87
Recognition of cellular implants by the brain's innate immune system. Immunol Cell Biol (2010) 0.87
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Mol Ther Nucleic Acids (2013) 0.86
RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica (2012) 0.86
Dendritic cells: cellular mediators for immunological tolerance. Clin Dev Immunol (2013) 0.86
The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT. J Immunol Methods (2010) 0.85
Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunol Immunother (2015) 0.85
Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system. Mediators Inflamm (2012) 0.85
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul Fibrinolysis (2004) 0.83
Efficient removal of LoxP-flanked genes by electroporation of Cre-recombinase mRNA. Biochem Biophys Res Commun (2003) 0.83
Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. Br J Haematol (2009) 0.82
Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother (2013) 0.82
Highly efficient mRNA-based gene transfer in feeder-free cultured H9 human embryonic stem cells. Cloning Stem Cells (2004) 0.82
Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol (2007) 0.82
Role of dendritic cells in HIV-immunotherapy. Curr HIV Res (2010) 0.81
A novel alternative spliced chondrolectin isoform lacking the transmembrane domain is expressed during T cell maturation. J Biol Chem (2003) 0.81
Fourth International Workshop on Haploidentical Transplants, Naples, Italy, July 8-10, 2004. Blood Cells Mol Dis (2004) 0.80
Cellular immunotherapy for cytomegalovirus and HIV-1 infection. J Immunother (2006) 0.80
Immunotherapy of hematological malignancies using dendritic cells. Bull Cancer (2008) 0.80
Gene expression signatures in CD34+-progenitor-derived dendritic cells exposed to the chemical contact allergen nickel sulfate. Toxicol Appl Pharmacol (2006) 0.79
Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. Mult Scler (2013) 0.79
Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Eur J Haematol (2014) 0.79
Rigler triad in gallstone ileus. CMAJ (2013) 0.79
Extracellular nucleoside diphosphate kinase NM23/NDPK modulates normal hematopoietic differentiation. Exp Hematol (2002) 0.79
Interferon α may be back on track to treat acute myeloid leukemia. Oncoimmunology (2013) 0.79
Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol Immunother (2011) 0.78
Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells. Leuk Res (2008) 0.78
Expression and localization of CHODLDeltaE/CHODLfDeltaE, the soluble isoform of chondrolectin. Cell Biol Int (2007) 0.78
HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med (2014) 0.77
Viral infections following allogeneic stem cell transplantation: how to cure the cure? Leuk Lymphoma (2010) 0.77
Cytokine transcript profiling in CD34+-progenitor derived dendritic cells exposed to contact allergens and irritants. Toxicol Lett (2005) 0.77
Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells. Mol Cancer (2006) 0.77